Rocket Lab Corporation (RKLB) › Analysis

Rocket Lab (RKLB) stock analysis, November 3, 2026: Neutron delay leaves a downtrend with earnings ahead

Published November 3, 2026 · updated 2026-11-10 · RKLB chart, levels and live analysis

Update, November 10, 2026

Since the November 3 report, Rocket Lab (RKLB) has rallied 2.58% on the day and is up 10.93% over the past five days, outpacing the S&P 500’s 0.81% decline in the same period, while the broader market remains under pressure from upcoming CPI data.

The picture holds; the stock remains below the 60.0‑level breakout threshold and still sits under the swing‑zone resistance at 61.03, with the 50‑day SMA at 62.37 unchanged. The daily close of 60.38 keeps the price beneath the swing‑zone swing point of 61.03, preserving the downside bias outlined in the assessment. A move above the 62.37 SMA on a weekly close would be required to shift the outlook.

Recent earnings disclosed a 73% YoY revenue jump to $267.83 million, yet an EPS miss of –$0.07 deepened the loss, prompting an 8% overnight drop (Benzinga). The stock’s volume is 7.7% below its 20‑day average, and the RSI sits at a neutral 53.2, indicating limited immediate momentum. The next earnings call on November 9 has already been priced in, leaving the current technical picture intact.

Rocket Lab Corporation (RKLB) trades at $53.69 after a 3.1% bounce today, but the stock is still down 27.4% over a month and 28.5% below its October 6, 2026 closing peak of $75.06, after the Neutron rocket slipped to 2027. The balance of evidence for the next two to six weeks leans negative, with medium conviction: the daily trend runs with the weekly downtrend, and the shares are lagging the S&P 500. Earnings on November 9 are the next test.

Why it matters

The event that broke the stock's momentum was the Neutron delay. On October 25, Rocket Lab pushed the rocket's first launch into 2027 with no firm date, after Yahoo Finance reported air pockets forming between carbon composite layers in the first-stage propellant tank domes. This was a repeat postponement, which is why it hurt. One Nasdaq piece argues it is better news than it sounds, since the flaw was found on the ground rather than in flight. The market has not been persuaded: the shares are about $21 below the October peak.

The bounce that followed shows how little was left to cushion the stock. On Tuesday, October 27, shares rose as much as 10% when the Neutron second stage and thrust module shipped to the Virginia launch site, and The Motley Fool noted Cantor Fitzgerald reiterating an overweight rating and a $122 price target. The stock closed that session at $58.31. It now sits well below that level. Operations are not the problem: Electron completed its 99th launch on November 2, the company's 20th mission of 2026. The market is repricing the timing of Neutron and the multiple paid for it, not the launch business.

Most of the recent weakness belongs to the stock itself. Over five days RKLB fell 7.9% while SPY fell 2.1%, so the market explains only a small part of the drop. No sector ETF figure is available to split out an industry effect. Over 50 days the stock trails SPY by 14.0 points, and year to date it is down 23.0% while SPY is up 10.5%. Today's 3.1% gain came with SPY up just 0.2%, but volume is running 56.5% below its 20-day average, so the bounce has little participation behind it.

The argument about RKLB is a valuation argument over a delay. The skeptical case, from Seeking Alpha, holds a Sell rating on inflated valuation and execution risk, and says further Neutron slippage could push the stock to new 52-week lows. The Motley Fool frames the same tension: a $2.36 billion backlog, about 2.5 times expected 2026 revenue of $959 million, set against a valuation near 40 times expected sales. The constructive case, also from The Motley Fool, points to that backlog, up 137% year over year and covering more than 90 launches, as reason to look at the stock below $60. Among 20 analysts the consensus is buy, with a mean price target of $102.15, a low of $64 and a high of $150. The price is 47.4% below the mean target, and even the lowest target is above where the stock trades. That gap says the analysts have not repriced yet. It does not say the stock is cheap.

What the evidence says

On the long term, the thesis is weakened but not destroyed. The business is still growing, with backlog up 137% and launch cadence intact, but the stock's story rests on Neutron, and that story just lost another year. Price is below both its 10-week and 40-week averages, below the 200-day average at $79.43 and the 50-day at $63.52, and 64.3% under the 52-week high of $150.23. This is a downtrend in which the stock has fallen 31.9% in six months. It is still 36.0% above the 52-week low of $39.48, so it is a drawdown, not a collapse.

For the next two to six weeks, the balance of evidence leans negative, with medium conviction (2 of 4 points). Two things carry it: the daily trend runs the same way as the weekly downtrend, and the stock lags the S&P 500 by 14.0% over 50 days. The RSI is 41, so the stock is weak but not oversold, and a further slide would not be stretched by that measure. The strongest case against this reading is the earnings report on November 9, where guidance of $250 to $265 million in revenue and a backlog near $2.36 billion could draw buyers back, and where the stock has already fallen 28.5% from its peak. That case does not tip the balance, because today's bounce came on thin volume and the price remains under every resistance level that matters. It is the reason conviction is not higher: earnings can move the stock sharply in either direction.

Levels that matter

The structure holds below $60, a round number where sellers have shown up on rallies. Just above it sit the 50-day average at $63.52 and a swing zone at $63.98. The weekly trend would end only above $63.98. Below the price, $50 is the first support, then $40 and the 52-week low at $39.48.

The downside breakout level is a daily close below $50. From there the only mapped target is the 52-week low at $39.48, against a stop at $61.03, which is $60 plus a quarter of the 14-day ATR of $4.11. That is a reward-to-risk of 1.0, well short of the 3 to 1 that makes a breakout worth the risk. No target on the map would reach 3 to 1; it would take a much tighter stop or a target far below the 52-week low. A daily close back above $61.03 would mean the breakdown was wrong.

What would change the picture

A weekly close above $63.98 would end the downtrend structure, and it would also put the price back above the 50-day average. The non-price fact that could do it is a firm, credible Neutron launch window for 2027, delivered with the Q3 results, since the open-ended delay is what the stock has been punished for. A new slip without a date would point the other way.

What to watch

Get a message when the RKLB picture changes — the agent team watches the levels and the news for you.Create a free account

More RKLB analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.